**Vasogen
                Inc.**
              
              **Contact:**
              Glenn
                Neumann, Investor Relations
              2505
                Meadowvale Blvd
              Mississauga,
                ON, Canada L5N 5S2
              tel:
                (905) 817-2004 fax: (905) 569-9231
              www.vasogen.com
                / investor@vasogen.com










***FOR
      IMMEDIATE RELEASE***







**Vasogen’s
      ACCLAIM Results to be Presented at the**


**Heart
      Failure Society of America Meeting in September**





**Mississauga,
      Ontario (June 29, 2006) -- Vasogen** **Inc. (NASDAQ:VSGN; TSX:VAS),** a leader
      in the research and commercial development of technologies targeting the chronic
      inflammation underlying cardiovascular and neurological disease, today announced
      that results from the Company’s ACCLAIM trial of its CelacadeTM technology
      (Celacade) in advanced chronic heart failure have been accepted for presentation
      at a late breaking clinical trial session of the 10th Annual Scientific Meeting
      of the Heart Failure Society of America (HFSA) being held in Seattle, Washington
      from September 10 to 13, 2006.





“An
      oral
      presentation at a HFSA late breaker clinical trial session provides another
      excellent opportunity to share the ACCLAIM results with the international
      cardiology community,” stated David Elsley, President and CEO of Vasogen. “We
      are currently completing the analysis of the ACCLAIM data in preparation for
      releasing full study results at this venue and at the World Congress of
      Cardiology in Barcelona, Spain, both in September. Based on our ongoing review
      of the data, we also look forward to providing an update on our plans to advance
      the commercial development of Celacade during our second quarter conference
      call
      in mid-July.”





The
      ACCLAIM trial enrolled 2,414 patients at 176 cardiac centers throughout North
      America, Europe, and Israel. The study was a double-blind, placebo-controlled
      trial designed to definitively assess the impact of Vasogen’s CelacadeTM
technology on the risk of death and cardiovascular hospitalizations in patients
      with advanced chronic heart failure. ACCLAIM enrolled patients with New York
      Heart Association Class II, III, or IV chronic heart failure and a mean left
      ventricular ejection fraction of less than 30%, indicating patients with
      advanced disease. Patients who participated in the ACCLAIM trial were taking
      pharmaceuticals that reflect the current standard-of-care and many had implanted
      cardiac defibrillators and/or cardiac resynchronization devices as clinically
      indicated. Study patients received monthly Celacade treatments in an outpatient
      clinic.





**About
      the Heart Failure Society of America**


The
      Heart
      Failure Society of America, Inc. represents the first organized effort by heart
      failure experts from the Americas to provide a forum for all those interested
      in
      heart function, heart failure, and congestive heart failure research and patient
      care. The Annual Scientific Meeting of the Heart Failure Society of America
      (HFSA) is the largest meeting in North America of scientists and healthcare
      professionals devoted to heart failure research.














**-more-**











**...page
      2, June 29, 2006**





**About
      Heart Failure**


Chronic
      heart failure (HF) is a major public health problem that imposes a significant
      burden in terms of morbidity, mortality, and the utilization of health care
      services. It is one of the most commonly diagnosed medical conditions affecting
      nearly 5 million Americans and 6.5 million Europeans. Each year, in the U.S.
      alone, 550,000 new cases of HF are diagnosed and nearly 300,000 deaths are
      associated with this condition. The five-year survival rate for patients with
      heart failure is only 50%. Approximately 6.5 million hospital days and up to
      15
      million office visits are for HF care each year in the United States alone.
      The
      health care costs associated with HF are staggering, with $29.6 billion in
      direct and indirect costs in the United States projected for 2006. Almost 72%
      ($21.3 billion) of this total represents costs associated with hospital and
      nursing home care, and physician and other health care professionals. More
      Medicare dollars are spent for the diagnosis and treatment of HF than for any
      other diagnosis.





**About
      Vasogen**


Vasogen
      is focused on the research and commercial development of technologies targeting
      the chronic inflammation underlying cardiovascular and neurological disease.
      The
      impact of the Company’s lead product, the CelacadeTM technology, on reducing
      mortality and morbidity in advanced heart failure patients was assessed in
      the
      recently completed ACCLAIM trial. Vasogen is also developing a new class of
      drugs for the treatment of neuro-inflammatory and neuro-vascular disorders.
      VP025, which is entering phase II clinical development, is the lead product
      candidate from this new class of drugs.





*Certain
      statements contained in this press release constitute “forward-looking
      statements” within the meaning of the United States Private Securities
      Litigation Reform Act of 1995. These statements include, without limitation,
      summary statements relating to results of the ACCLAIM trial in patients with
      chronic heart failure, statements on our future plans for Celacade and
      publication of results from the ACCLAIM trial, statements, concerning our
      partnering activities, strategy, future operations, future financial position,
      future revenues, projected costs, prospects, plans and objectives of management.
      Results disclosed are based on data analyzed to date and may not be confirmed
      upon full analysis of the detailed results of the ACCLAIM trial and additional
      information relating to safety and efficacy of Celacade may be discovered upon
      further analysis of trial data and upon further review and analysis of
      additional trial data. In some cases, you can identify forward-looking
      statements by terminology such as “may”, “will”, “should”, “expects”, “plans”,
“anticipates”, “believes”, “estimated”, “predicts”, “potential”, “continue”,
“intends”, “could”, or the negative of such terms or other comparable
      terminology. You should not place undue reliance on our forward-looking
      statements which are subject to a multitude of risks and uncertainties that
      could cause actual results, future circumstances or events to differ materially
      from those projected in the forward-looking statements. These risks include,
      but
      are not limited to, the outcome of further analysis of the ACCLAIM trial
      results, risks associated with the outcome of our research and development
      programs, the adequacy, timing and results of our clinical trials, the need
      for
      additional capital and the effect of capital market conditions and other factors
      on capital availability, the potential dilutive effects of any financing,
      including the convertible notes we issued in October 2005, the regulatory
      approval process, competition, securing and maintaining corporate alliances,
      market acceptance of our products, the availability of government and insurance
      reimbursements for our products, the strength of intellectual property, reliance
      on subcontractors and key personnel, losses due to fluctuations in the
      U.S.-Canadian exchange rate, and other risks detailed from time to time in
      our
      public disclosure documents or other filings with the Canadian and U.S.
      securities commissions or other securities regulatory bodies. Additional risks
      and uncertainties relating to our Company and our business can be found in
      the
“Risks Factors” section of our Annual Information Form and Form 40F for the year
      ended November 30, 2005 as well as in our later public filings. The
      forward-looking statements are made as of the date hereof, and we disclaim
      any
      intention and have no obligation or responsibility, except as required by law,
      to update or revise any forward-looking statements, whether as a result of
      new
      information, future events or otherwise. Numerical values indicating the
      statistical significance ("p-values") of results included in this press release
      are based on analyses that do not account for endpoint multiplicity, and
      therefore are for information only and are not intended to be used for any
      future regulatory submissions or in any future product labeling in jurisdictions
      where such uses are prohibited.*








**###**